Lev Becker, PhD
University of Chicago
Department of Cancer Research

AREA(S) OF FOCUS:

Capitalizing on the body's innate immunity to treat human diseases

The Becker lab takes a cross-functional approach for studying immune cells and developing therapeutics for inflammatory diseases such as cancer, atherosclerosis, & obesity.

KEY RESEARCH AREAS:

Selective anti-cancer agents
Explore the use of elastase, a protein released by immune cells, to activate cancer cell death pathways while sparing healthy cells.

Signaling within tumor-associated cells
Elucidate estrogen signaling in tumor-associated immune cells in breast cancer progression.

Obesity as a risk factor for breast cancer
Study the link between obesity and pro-inflammatory factors in breast cancer patients.

ELANE Platform



ENTREPRENEURIAL SUCCESS:

Onchilles Pharma uses myeloid cells to develop cancer treatment immunotherapies.

The pipeline includes a first-in-class therapeutic based on elastase (ELANE) which activates cell death pathways in cancer cells.

Onchilles Pharma has raised $7.2 million in funding.

RMark Bio created a framework for analyzing global healthcare data with internal clinical research to advance partnerships and engagement strategies for commercialization efforts.

RMark Bio raised $6.6 million in funding before being acquired by Within3 in 2021.

MacroLogic Inc.

MacroLogic is developing a device to selectively deliver drugs to immune cells called macrophages for treatment of many diseases, including cancer.